These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32157673)

  • 1. Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy.
    Gillis RME; Wammes-van der Heijden EA; Schelhaas HJ; Tan IY; Festen DAM; Majoie MHJM
    Acta Neurol Belg; 2021 Jun; 121(3):677-684. PubMed ID: 32157673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.
    Foo EC; Geldard J; Peacey C; Wright E; Eltayeb K; Maguire M
    Epilepsy Behav; 2019 Oct; 99():106505. PubMed ID: 31493736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation.
    Adewusi J; Burness C; Ellawela S; Emsley H; Hughes R; Lawthom C; Maguire M; McLean B; Mohanraj R; Oto M; Singhal S; Reuber M
    Epilepsy Behav; 2020 May; 106():106967. PubMed ID: 32179501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.
    Steinig I; von Podewils F; Möddel G; Bauer S; Klein KM; Paule E; Reif PS; Willems LM; Zöllner JP; Kunz R; Runge U; Kurlemann G; Schubert-Bast S; Rosenow F; Strzelczyk A
    Epilepsia; 2017 Jul; 58(7):1208-1216. PubMed ID: 28480518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis.
    Hirsch M; Hintz M; Specht A; Schulze-Bonhage A
    Seizure; 2018 Oct; 61():98-103. PubMed ID: 30118932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
    Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRIVEST: A 'real-world' observational, single-centre study investigating the efficacy, safety and tolerability of Brivaracetam.
    Naddell S; Manuel M; Cavill R; White P; Sieradzan K
    Epilepsy Behav; 2023 Jan; 138():108985. PubMed ID: 36442261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center.
    Green SF; Hare N; Kassam M; Rugg-Gunn F; Koepp MJ; Sander JW; Rajakulendran S
    Epilepsy Behav; 2022 Oct; 135():108868. PubMed ID: 35985166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy-A monocenter survey.
    Steinhoff BJ; Bacher M; Bucurenciu I; Hillenbrand B; Intravooth T; Kornmeier R; Kurth C; Stockinger J; Staack AM
    Seizure; 2017 May; 48():11-14. PubMed ID: 28364655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
    Benbadis S; Klein P; Schiemann J; Diaz A; Elmoufti S; Whitesides J
    Epilepsy Behav; 2018 Mar; 80():129-134. PubMed ID: 29414542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial.
    Arnold S; Laloyaux C; Schulz AL; Elmoufti S; Yates S; Fakhoury T
    Epilepsy Res; 2020 Oct; 166():106404. PubMed ID: 32731118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
    Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy.
    Fonseca E; Guzmán L; Quintana M; Abraira L; Santamarina E; Salas-Puig X; Toledo M
    Epilepsy Behav; 2020 Jan; 102():106657. PubMed ID: 31731108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive brivaracetam - A prospective audit of outcomes from an epilepsy clinic.
    Stephen L; Brodie MJ
    Epilepsy Behav; 2021 Mar; 116():107746. PubMed ID: 33517200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of lifetime antiepileptic drug treatment history on efficacy and tolerability of adjunctive brivaracetam in adults with focal seizures: Post-hoc analysis of a randomized, placebo-controlled trial.
    Klein P; McLachlan R; Foris K; Nondonfaz X; Elmoufti S; Dimova S; Brandt C
    Epilepsy Res; 2020 Nov; 167():106369. PubMed ID: 32717713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.
    Ben-Menachem E; Baulac M; Hong SB; Cleveland JM; Reichel C; Schulz AL; Wagener G; Brandt C
    Epilepsy Res; 2021 Feb; 170():106526. PubMed ID: 33461041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
    Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow-up.
    Strzelczyk A; Zaveta C; von Podewils F; Möddel G; Langenbruch L; Kovac S; Mann C; Willems LM; Schulz J; Fiedler B; Kurlemann G; Schubert-Bast S; Rosenow F; Beuchat I
    Epilepsia; 2021 Dec; 62(12):2994-3004. PubMed ID: 34608628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis.
    Brandt C; Klein P; Badalamenti V; Gasalla T; Whitesides J
    Epilepsy Behav; 2020 Feb; 103(Pt A):106864. PubMed ID: 31937513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study.
    Asadi-Pooya AA; Sperling MR; Chung S; Klein P; Diaz A; Elmoufti S; Schiemann J; Whitesides J
    Epilepsy Res; 2017 Mar; 131():70-75. PubMed ID: 28279891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.